PMID: 15217553Jun 26, 2004Paper

Nonmyeloablative stem cell transplantation: lessons from the first decade of clinical experience

Current Hematology Reports
Avichai Shimoni, Arnon Nagler

Abstract

Allogeneic stem cell transplantation is an effective and potentially curative therapy for hematologic malignancies. However, the procedure may be associated with significant morbidity and mortality resulting from toxicity of the conditioning regimen, limiting it to younger patients in good medical conditioning. Over the past decade, nonmyeloablative and reduced-intensity conditioning regimens have been designed to reduce toxicity and allow stem cell transplantation in elderly and medically infirm patients. These are relatively nontoxic and tolerable regimens designed not to maximally eradicate the malignancy, but rather to provide sufficient immune suppression to achieve engraftment and to allow induction of graft-versus-leukemia effect as the primary treatment. After transplantation, immune interventions are often required to hasten this graft-versus-leukemia effect. In this review, we discuss emerging data defining the relative toxicities and outcomes after nonmyeloablative transplantation in certain settings and our approach to patient selection and post-transplant immune interventions trying to improve overall outcome.

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.